General inflammatory markers

General inflammatory markers are a heterogeneous group of biological indicators used to assess the presence and severity of systemic inflammation. This category encompasses acute-phase proteins synthesized by the liver, such as C-reactive protein (CRP) and serum amyloid A, as well as physiological measurements like the erythrocyte sedimentation rate (ESR) and various circulating cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) (StatPearls, 2023; PMC, 2021). These markers are upregulated in response to tissue damage, infection, or autoimmune triggers, serving as vital tools for diagnosing conditions like sepsis, rheumatoid arthritis, and inflammatory bowel disease (NIH, 2022). While individual components like IL-6 and TNF-α are specific therapeutic targets for monoclonal antibodies (e.g., tocilizumab and infliximab), the collective term "General inflammatory markers" refers to a diagnostic class rather than a single molecular target. Their primary clinical utility lies in monitoring disease progression and evaluating the efficacy of anti-inflammatory treatments, although their lack of specificity often requires correlation with clinical findings (PubMed, 2023).

Other names

Inflammatory biomarkersAcute phase reactantsSystemic inflammatory markersInflammatory indicesMarkers of inflammation

Drugs modulate these markers by inhibiting pro-inflammatory cytokines (e.g., IL-6, TNF-alpha), blocking cyclooxygenase enzymes (COX-1/2), or activating glucocorticoid receptors to suppress the systemic inflammatory cascade.